Skip to main content

Advertisement

SpringerLink
Log in

Towards a prevention model of health care

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Health-care budgets are largely spent on treating the complications of chronic diseases, many of which have preventable risk factors. Here, we discuss some of the key issues in the necessary move towards a 'prevention model' of health care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ross, J. S. et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320–368 (2009).

    Article  CAS  Google Scholar 

  2. Yazicki, Y. & Simsek, I. Treatment options for rheumatoid athritis beyond TNF-α inhibitors. Exp. Rev. Clin. Pharm. 3, 663–666 (2010).

    Article  Google Scholar 

  3. Breckenridge, A., Mello, M. & Psaty, B. M. New horizons in pharmaceutical regulation. Nature Rev. Drug Discov. 11, 501–502 (2012).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The views expressed are personal and do not necessarily reflect the views of any of the regulatory agencies.

Author information

Authors and Affiliations

  1. Department of Health, Alasdair Breckenridge was previously Chairman of the Medicines and Healthcare products Regulatory Agency, London, UK; he is currently Chairman of the UK Emerging Science and Bioethics Advisory Committee, Richmond House, 79 Whitehall, London SW1 2NS, UK.,

    Alasdair Breckenridge

  2. Department of Health, he is currently Chairman of the UK Emerging Science and Bioethics Advisory Committee, Richmond House, 79 Whitehall, London SW1 2NS, UK.,

    Alasdair Breckenridge

  3. Hans-Georg Eichler is Senior Medical Officer at the European Medicines Agency, 7 Westferry Circus, London E14 4HB, UK.,

    Hans-Georg Eichler

Authors
  1. Alasdair Breckenridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans-Georg Eichler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Alasdair Breckenridge or Hans-Georg Eichler.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

US Food and Drug Administration (Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease)

US Food and Drug Administration (In Vitro Companion Diagnostic Devices)

European Medicines Agency (Reflection paper on co-development of pharmacogenomics biomarkers and assays in the context of drug development)

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)

Mini-Sentinel

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breckenridge, A., Eichler, HG. Towards a prevention model of health care. Nat Rev Drug Discov 12, 563–564 (2013). https://doi.org/10.1038/nrd4077

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4077

  • Springer Nature Limited

This article is cited by

Search

Navigation